InSilico Medicine Cayman TopCo 3696

AI, cloud and HPC are accelerating virtual screening and precision medicine, expanding adoption across pharma, biotech and CROs in oncology, neurology, rare and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "In-Silico Drug Discovery Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global In-Silico Drug Discovery Market to Reach US$6 Billion by 2030 The global in-silico drug discovery market was valued at US$3.3 billion in 2024 and i

As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has become the latest Top Drug, underscoring the industry's momentum and commercial potential. To further advance long-acting and precise weight management, the industry has proposed a combination strategy using GIPR (glucose-dependent insulinotropic polypeptide re

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

AI is accelerating drug screening, precision therapies and clinical trials, driven by cloud computing, rising R&D costs and demand for complex-disease treatments.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "AI in Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for AI in Drug Discovery was estimated at US$2.4 Billion in 2025 and is projected to reach US$14.3 Billion by 2032, growing at a CAGR of 28.8% from 2025 to 2032. This

Insilico Medicine Cayman TopCo (SEHK:3696) advanced its AI-discovered drug rentosertib into Phase III trials for idiopathic pulmonary fibrosis in China. The company reported that rentosertib is the first drug fully discovered and designed by its AI platform to reach Phase III testing. New research from Insilico Medicine indicated rentosertib may help reverse biological age markers in treated patients with fibrosis. The move of rentosertib into Phase III and its reported impact on biological...

AI drug discovery firm Insilico Medicine is profitable, publicly listed in Hong Kong, and running the drug industry's most consequential experiment.

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the publication of a landmark study in Cellintroducing an open AI toolkit, including LongevityBench, Longevity-LLMs and LongevityClaw designed to accelerate research and therapeutic development in aging and longevity.

Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to broaden the exposure to "emerging technology trends, including opportunities across the AI value chain", announced on 18 August 2026. All changes will be implemented after the market close on 11 September 2026 (Friday) and take effect on 14 September 2026 (Mo

Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of US$106.3 million in the first half of 2026, representing a substantial year-over-year increase of 287.2%, with a gross profit margin of 90.3%. During the period, the Company realized a net profit of US$35.54 million and an adjusted net profit (non-IFRS measure) of

Nirav Jhaveri, Chief Financial Officer Nirav Jhaveri, Chief Financial Officer Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Com

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital International (MSCI). The change will take effect as of the close of August 31, 2026.

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), today announced the launch of its Virtual Aging Cell (VAC) Webpage alongside the preview of the company's Multi-Agent driven VAC platform.

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inhibitor of lipoprotein(a), or Lp(a), as a preclinical candidate (PCC) for the management of cardiovascular risks. Notably, this marks the company's 9th PCC nomination announced since 2026, showcasing the enhanced efficiency and scalability that generat

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended June 30, 2026 and provide a business update.

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM9077, the AI-empowered, potential first-in-class Target Y inhibitor with pipeline-in-a-drug potential, as a Preclinical Candidate (PCC) for the treatment of ocular diseases including dry Age-Related Macular Degeneration (dry AMD), uveitis, and dry eye disease. As the 32nd PCC nominated since 2021, ISM9077 boasts potent inhibition

InSilico Medicine Cayman TopCo stock has risen 12.4% over the past month, while its valuation checks send mixed messages, with a Discounted Cash Flow (DCF) estimate pointing to upside and market multiples suggesting the shares are not cheap on traditional metrics. The 12.4% gain over the past month signals growing optimism around InSilico Medicine Cayman TopCo after a weaker recent week. Progress on AI designed drug candidates like ISM6331 and ISM9528 can support expectations for future cash...

As general-purpose and domain-specific AI models rapidly infiltrate drug discovery, one critical question looms over the pharmaceutical sector: Can these models actually discover drugs, or are they just good at taking tests? Today, most publicly available AI benchmarks suffer from severe data contamination, where models achieve artificially inflated scores simply by memorizing test questions present in their training data, only to fail when faced with real-world drug candidate decisions.

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), for the treatment of adult patients with unresectable malignant pleural mesothelioma whose disease has progressed on or after prior treatment with anti-PD-1